drugset / Trial / NCT03917459

COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure

NCT03917459 ↗

Phase 3 Completed 27 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study was to determine the effect of sacubitril/valsartan (LCZ696) vs. Enalapril on improvement in erectile function and ability in male patients with chronic heart failure with reduced ejection fraction and erectile dysfunction.

Timeline

Start
2019-04-16
Primary completion
2021-05-25
Completion
2021-05-25

Outcome

Missed primary endpoint

registry analysis (other test); LCZ696 vs Enalapril; p = 0.3432; LS mean of treatment difference 2.9 (95% CI -3.29 to 9.01) NCT03917459 ↗

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enalapril Other / unclassified 10 mg —
Subject LCZ696 Unknown 200 mg —